摘要
目的:探讨血管紧张素Ⅱ受体拮抗剂的进展与临床评价。方法:参考国内外文献对血管紧张素Ⅱ受体拮抗剂的进展和上市品种的临床评价进行研究和分析。结果与结论:血管紧张素Ⅱ受体拮抗剂的问世和发展,为抑制肾素-血管紧张素-醛固酮系统寻找到了一类新型药物,是继β-受体拮抗剂、钙拮抗剂、血管紧张素换转酶抑制剂后的又一新的突破,它拓展了抗高血压治疗的新途径,在防治高血压及避免靶器官损害方面具有广阔的应用前景。
OBJECTIVE:To discuss the progress and clinical evaluation of angiotensin Ⅱ receptor antagonists(ARA). METHODS: With reference to relevent literature, the research progress and the agents in the market of ARA were described and analysed. RESULTS & CONCLUSION: With the emersion and development of ARA, a kind of new drugs has been found out to inhibit the activity of renin-angiotensin-aldosterone system. ARA succeeds β-receptor antagonists, calcium ion antagonists and angiotensinase inhibiting agents as a new break through in antihypertensive therapy, and the use of ARA has extensive prospects in prevention and treatment of hypertension without damage to target organs.
出处
《中国医院用药评价与分析》
2001年第1期25-28,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
